Retatrutide Cuts Weight 20.8% in Type 2 Diabetes, and Lilly Plans to File It as a Biologic
The efficacy is the headline. The filing route and a sensory side effect are the details that will shape the label.
Type 2 Diabetes
Qatar Became Foundayo’s Sixth Market as Lilly Claimed an Edge Over Oral Semaglutide 25 mg
Approvals market by market, and data built to shape the comparison with a Novo dose that has not launched.
Novo Paid $300 Million Upfront for a Weekly GLP-1/GIP Pill That Has Not Yet Entered Phase 1
Novo paid a clean, large upfront for a once-weekly pill whose convenience advantage it cannot yet prove in people.
NICE Withdrew Four Appraisals Because the Medicine Went Off Patent.
Going off patent now costs a medicine its named appraisal. And the withdrawal is a routing decision carrying no right of appeal.
NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option
QuickAccess read/Endocrine & Metabolic/Peptide NICE Backed a Weekly Insulin Before It Has a Licence, Then Told Prescribers to Pick the Cheapest Option Athithi Verma· 25 August 2026· 2 min read· Synopulse NICE published final draft guidance recommending insulin efsitora alfa (Onswik), from Eli Lilly, for adults with type 2 diabetes. Given once weekly by pre-filled … Read more